SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab

Objectives: In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed. Methods: Patients in the intervention groups receive...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Martin Heller, Clara Henrici, Judith Büttner, Sebastian Leube, Isabelle Treske, Petra Pospischil, Michael Doll, Ilka Schanz, Agnes Hallier, Eva Herrmann, Michael Schmidt, Christoph Sarrazin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-04-01
Edice:	International Journal of Infectious Diseases
Témata:	COVID-19 Bamlanivimab Casirivimab Imdevimab Antibody therapy Viral load
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S1201971223000127
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!